Companie's Offerings in the Hyper-personalized Medicine Market
Simplify analysis. Strengthen strategy. Own the Hyper-personalized Medicine Market view - Access the dashboard.
| Company | Description |
| Illumina, Inc. | Its offerings range from high-throughput sequencing instruments to clinical informatics & molecular diagnostic tools. |
| Roche Diagnostics | This firm focuses on next-generation sequencing (NGS), liquid biopsies, & digital pathology to allow precise, personalized care. |
| Novartis | This company invested in the integration of advanced technology, data analytics, & molecular science. |
| Exact Sciences | A player offers molecular diagnostics to guide treatment decisions based on a patient's specific cancer biology. |
| AstraZeneca PLC | It specializes in next-gen therapeutics & companion diagnostics (CDx). |
| Bristol-Myers Squibb Co. (BMS) | This mainly facilitates precision medicine in oncology, hematology, and immunology. |
| Amgen Inc. | Its offerings cover integration of advanced human genetics, artificial intelligence (AI), & molecular biology. |
| QIAGEN | This unveiled solutions in ecology, neurological disorders, & chronic diseases by using Next-Generation Sequencing (NGS), digital PCR (dPCR), & bioinformatics. |
| Pfizer Inc. | A company emphasizes advanced analytics, AI, & genetic profiling, especially in oncology, rare diseases, & mRNA technologies. |
| NeoGenomics, Inc. | This mainly offers over 500 tests across different modalities to guide targeted treatment. |
What are the Latest Developments in the Hyper-personalized Medicine Market?
- In April 2026, the Mohammed VI Foundation for Science and Health (FM6SS) rolled out a new precision medicine hub to combine genomics & patient care.
- In February 2026, Providence Therapeutics announced a world-first clinical trial assessing personalized mRNA cancer vaccines for children with advanced & treatment-resistant brain tumors.
- In January 2026, Mendra launched an $82 million Series A fundraising round to expand the development of rare disease therapies with AI.
Hyper-personalized Medicine Market- Supply Chain Analysis
R&D
- The market covers patient profiling & molecular characterization, then target identification & therapeutic designing, with various clinical stages & finally implementation.
- Key Players: Nucleus Genomics, CRISPR Therapeutics, Tempus, etc.
Clinical Trials & Regulatory Approvals
- Includes preclinical validation, biomarker discovery, N-of-1 Trial designing, then exploring trials, like a basket trial, & further collect RWE, with approvals from various regulatory bodies, like FDA, EMA, etc.
- Key Players: University of Florida, Fundacion Clinic per a la Recerca Biomédica, National University of Singapore, etc.
Patient Support & Services
- Firms are providing tailored treatment plans, AI-enabled diagnostics, real-time monitoring via wearables, & precision nutrition.
- Key Players: Indegene, Infosys, Cognizant, etc.
Market Trends
The global hyper-personalized medicine market size was estimated at USD 3.24 trillion in 2025 and is predicted to increase from USD 3.71 trillion in 2026 to approximately USD 12.59 trillion by 2035, expanding at a CAGR of 14.55% from 2026 to 2035.
Keypoints
- Company Overview
- Locations Subsidiaries/Geographic reach
- Key Executives
- Company Financials
- Patents registered
- SWOT Analysis
- Applications Catered
- Strategic collaborations
- Recent Developments
- Competitive Benchmarking